CalciMedica, Inc. Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Recognized in Earnings
CalciMedica, Inc. (CALC) reported Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Recognized in Earnings of $0 for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-13.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings · last filed 2024-05-13
- CalciMedica, Inc. other-than-temporary impairment loss, debt securities, available-for-sale, recognized in earnings for the quarter ending 2024-03-31 was $0.00.
- CalciMedica, Inc. other-than-temporary impairment loss, debt securities, available-for-sale, recognized in earnings for the quarter ending 2022-12-31 was $0.00.
- CalciMedica, Inc. other-than-temporary impairment loss, debt securities, available-for-sale, recognized in earnings for the quarter ending 2022-09-30 was $0.00.
- CalciMedica, Inc. other-than-temporary impairment loss, debt securities, available-for-sale, recognized in earnings for the quarter ending 2022-06-30 was $0.00.
- CalciMedica, Inc. other-than-temporary impairment loss, debt securities, available-for-sale, recognized in earnings for fiscal 2022 was $0.00.
- CalciMedica, Inc. other-than-temporary impairment loss, debt securities, available-for-sale, recognized in earnings for fiscal 2021 was $0.00.
- CalciMedica, Inc. other-than-temporary impairment loss, debt securities, available-for-sale, recognized in earnings for fiscal 2020 was $0.00.
- CalciMedica, Inc. other-than-temporary impairment loss, debt securities, available-for-sale, recognized in earnings for fiscal 2019 was $0.00.
| Period end | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Recognized in Earnings 3 month | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Recognized in Earnings 6 month | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Recognized in Earnings 9 month | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Recognized in Earnings 12 month |
|---|---|---|---|---|
| 2024-03-31 | $0.00 10-Q · filed 2024-05-13 | |||
| 2023-09-30 | $0.00 10-Q · filed 2023-11-09 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $0.00 derived: sum of 2 quarters · filed 2023-03-09 | $0.00 derived: sum of 3 quarters · filed 2023-03-09 | $0.00 10-K · filed 2023-03-09 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $0.00 derived: sum of 2 quarters · filed 2022-11-10 | $0.00 10-Q · filed 2022-11-10 | $0.00 derived: sum of 4 quarters · filed 2023-03-09 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $0.00 10-Q · filed 2022-08-12 | $0.00 derived: sum of 3 quarters · filed 2023-03-09 | $0.00 derived: sum of 4 quarters · filed 2023-03-09 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-12 | $0.00 derived: sum of 2 quarters · filed 2023-03-09 | $0.00 derived: sum of 3 quarters · filed 2023-03-09 | $0.00 derived: sum of 4 quarters · filed 2023-03-09 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $0.00 derived: sum of 2 quarters · filed 2023-03-09 | $0.00 derived: sum of 3 quarters · filed 2023-03-09 | $0.00 10-K · filed 2023-03-09 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $0.00 derived: sum of 2 quarters · filed 2021-11-12 | $0.00 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $0.00 10-Q · filed 2021-08-12 | ||
| 2021-03-31 | $0.00 10-Q · filed 2021-05-14 | |||
| 2020-12-31 | $0.00 10-K · filed 2022-03-11 | |||
| 2019-12-31 | $0.00 10-K · filed 2021-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |